Phase II/III Trial of Cetuximab Plus Irinotecan Synchronously/Subsequently in Patients With KRAS Wild-type Metastatic Colorectal Cancer: an Randomized, Open-label, Multicenter, Prospective Study

Trial Profile

Phase II/III Trial of Cetuximab Plus Irinotecan Synchronously/Subsequently in Patients With KRAS Wild-type Metastatic Colorectal Cancer: an Randomized, Open-label, Multicenter, Prospective Study

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Cetuximab (Primary) ; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Shanghai Zhangjiang Biotechnology
  • Most Recent Events

    • 02 Jun 2017 Primary endpoint (Overall response rate) has been met, according to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 21 Dec 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top